Literature DB >> 22178787

Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction.

Frank González1.   

Abstract

Chronic low-grade inflammation has emerged as a key contributor to the pathogenesis of Polycystic Ovary Syndrome (PCOS). A dietary trigger such as glucose is capable of inciting oxidative stress and an inflammatory response from mononuclear cells (MNC) of women with PCOS, and this phenomenon is independent of obesity. This is important because MNC-derived macrophages are the primary source of cytokine production in excess adipose tissue, and also promote adipocyte cytokine production in a paracrine fashion. The proinflammatory cytokine tumor necrosis factor-α (TNFα) is a known mediator of insulin resistance. Glucose-stimulated TNFα release from MNC along with molecular markers of inflammation are associated with insulin resistance in PCOS. Hyperandrogenism is capable of activating MNC in the fasting state, thereby increasing MNC sensitivity to glucose; and this may be a potential mechanism for promoting diet-induced inflammation in PCOS. Increased abdominal adiposity is prevalent across all weight classes in PCOS, and this inflamed adipose tissue contributes to the inflammatory load in the disorder. Nevertheless, glucose ingestion incites oxidative stress in normal weight women with PCOS even in the absence of increased abdominal adiposity. In PCOS, markers of oxidative stress and inflammation are highly correlated with circulating androgens. Chronic suppression of ovarian androgen production does not ameliorate inflammation in normal weight women with the disorder. Furthermore, in vitro studies have demonstrated the ability of pro-inflammatory stimuli to upregulate the ovarian theca cell steroidogenic enzyme responsible for androgen production. These findings support the contention that inflammation directly stimulates the polycystic ovary to produce androgens. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22178787      PMCID: PMC3309040          DOI: 10.1016/j.steroids.2011.12.003

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  46 in total

1.  Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling.

Authors:  Anne Corbould; Young-Bum Kim; Jack F Youngren; Celia Pender; Barbara B Kahn; Anna Lee; Andrea Dunaif
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-12-21       Impact factor: 4.310

2.  Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome.

Authors:  F Gonzalez; K Thusu; E Abdel-Rahman; A Prabhala; M Tomani; P Dandona
Journal:  Metabolism       Date:  1999-04       Impact factor: 8.694

3.  Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome.

Authors:  Frank González; Neal S Rote; Judi Minium; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

4.  Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance.

Authors:  Enrico Carmina; Salvo Bucchieri; Antonella Esposito; Antonio Del Puente; Pasquale Mansueto; Francesco Orio; Gaetana Di Fede; Giovambattista Rini
Journal:  J Clin Endocrinol Metab       Date:  2007-04-03       Impact factor: 5.958

5.  Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation.

Authors:  Ilhan Tarkun; Berrin C Arslan; Zeynep Cantürk; Erdem Türemen; Tayfun Sahin; Can Duman
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

6.  Divergent effects of weight reduction and oral anticonception treatment on adrenergic lipolysis regulation in obese women with the polycystic ovary syndrome.

Authors:  H Wahrenberg; I Ek; S Reynisdottir; K Carlström; A Bergqvist; P Arner
Journal:  J Clin Endocrinol Metab       Date:  1999-06       Impact factor: 5.958

7.  Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome.

Authors:  Frank González; Judi Minium; Neal S Rote; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2005-06-28       Impact factor: 5.958

8.  Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice.

Authors:  S Franckhauser; I Elias; V Rotter Sopasakis; T Ferré; I Nagaev; C X Andersson; J Agudo; J Ruberte; F Bosch; U Smith
Journal:  Diabetologia       Date:  2008-04-24       Impact factor: 10.122

9.  Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome.

Authors:  Frank González; Neal S Rote; Judi Minium; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2006-02-07       Impact factor: 5.958

10.  In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome.

Authors:  F González; N S Rote; J Minium; J P Kirwan
Journal:  J Endocrinol       Date:  2006-03       Impact factor: 4.286

View more
  101 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.

Authors:  Nadia Rashid; Aruna Nigam; Pikee Saxena; S K Jain; Saima Wajid
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

Review 3.  New insights into insulin: The anti-inflammatory effect and its clinical relevance.

Authors:  Qiang Sun; Jia Li; Feng Gao
Journal:  World J Diabetes       Date:  2014-04-15

4.  How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology.

Authors:  P Moghetti; E Carmina; V De Leo; A Lanzone; F Orio; R Pasquali; V Toscano
Journal:  J Endocrinol Invest       Date:  2015-04-03       Impact factor: 4.256

5.  Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.

Authors:  İsmail Demi R; Aslı Guler; Pınar Alarslan; Ahmet Murat Isil; Ozge Ucman; Behnaz Aslanipour; Mehmet Calan
Journal:  Endocrine       Date:  2019-06-01       Impact factor: 3.633

Review 6.  Control strategies in systemic metabolism.

Authors:  Jessica Ye; Ruslan Medzhitov
Journal:  Nat Metab       Date:  2019-10-07

Review 7.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

8.  Immunophenotypic profile of leukocytes in hyperandrogenemic female rat an animal model of polycystic ovary syndrome.

Authors:  Mohadetheh Moulana
Journal:  Life Sci       Date:  2019-01-29       Impact factor: 5.037

9.  Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis.

Authors:  S Yavuz; T Akdeniz; V Hancer; M Bicakcigil; M Can; G Yanikkaya-Demirel
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

Review 10.  The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis.

Authors:  Hannah E Young; Wendy E Ward
Journal:  Reprod Sci       Date:  2020-09-10       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.